J&J’s Carvykti Claims Broadest CAR-T Label In Multiple Myeloma

 
• By Bridget Silverman
multiple myeloma
Carvykti can be used in an earlier line of therapy than Bristol Myers Squibb/2seventy bio’s rival CAR-T Abecma. • Source: Shutterstock

More from Approvals

More from Product Reviews